Abstract
“… this adequately powered RCT fails to support the current widespread practice of using subcutaneous ketamine as an adjuvant to opioids in the management of refractory pain in patients with advanced cancer.” This is the conclusion of Prof. Janet Hardy and her colleagues following completion of a large and rigorous randomized, double-blind, placebo-controlled trial of subcutaneous ketamine in cancer related pain - 185 patients treated for up to 5 days (1).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
